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In the 1960s, when the initial trials of combination
chemotherapy began to prolong remission duration in child-
hood acute lymphoblastic leukaemia, an increasing incidence
of central nervous system relapse was noted with rates
between 50 and 70% (Hardisty & Norman, 1967; Evans et
al., 1970; Hustu et al., 1973). Overt CNS leukaemia appeared
difficult to control, but its major significance was that it was
almost invariably followed by bone marrow relapse, whilst
deaths from neurological dysfunction were quite rare, even in
the presence of multiple CNS recurrences (Ortega et al.,
1987). Symptom-free remission post overt CNS relapse was
short and, in the MRC trials between 1977 and 1987, only 23
of 116 children survived without subsequent event. The
length of first remission and whether relapse occurred on or
off therapy significantly determined the chance of survival.
There were serious long-term sequelae with 50% of survivors
severely disabled neurologically, educationally or on both
counts. A more favourable salvage rate of over 50% has
been reported by the Paediatric Oncology Group but it is in
a series with a shorter follow-up time (Land et al., 1985). The
full impact of disability caused by therapy requires long-term
follow-up.
Prevention of CNS relapse has clearly been deemed a
better option than salvage post relapse. Although for some
time controversial it is now accepted that CNS involvement
results from leukaemic cells lying in the walls of superficial
arachnoid veins which then migrate into the surrounding
adventitia. As cell numbers increase the arachnoid trabeculae
are destroyed with subsequent penetration of cerebrospinal
fluid channels over the surface of the brain. Further exten-
sion can lead to direct infiltration of neural tissue. Rarely,
isolated nodular infiltrates can occur. The leukaemic cells
lying adjacent to the arachnoid veins are not reached by
adequate concentrations of standard dose leukaemic therapy,
that is, they lie in a so-called pharmacological sanctuary.
Pinkel and his group at St Jude's Childrens Research Hos-
pital postulated and then demonstrated that presymptomatic
CNS irradiation could dramatically reduce overt CNS relapse
to less than 10% (Aur et al., 1971; Hustu et al., 1973).
Whether such treatment prevents subsequent haematological
relapse is more controversial. The Cancer and Leukaemia
Group B in a randomised study showed a median remission
duration of 26 months for those receiving intrathecal
methotrexate compared with only 15 months for the group
which did not (Holland & Glidwello, 1972). In the St Jude's
series of studies, there was a 2-3.5-fold increased risk of
haematological relapse for those children who experienced an
isolated CNS relapse. In the Total VI Study, 58% of patients
who had received presymptomatic craniospinal irradiation
remained in remission 8-11 years post-diagnosis, compared
with only 35% of those given CNS treatment at the time of
overt relapse (George et al., 1985). In contrast, the CCGF101
study contained one arm in which patients were treated only
with intrathecal methotrexate. This group had an increased
CNS relapse rate, but neither marrow relapse nor overall
survival rates were significantly affected after medium-term
follow-up (Ortega et al., 1987). However, these patients were
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recalled for further therapy when the increased CNS relapses
became obvious. With increasingly intensive induction and
consolidation therapy longer term follow-up (beyond 10
years) is necessary in order to assess the full impact of any
overt CNS disease upon total survival. For some patients it
would appear that occult CNS leukaemia is the only site of
residual disease which, if not eradicated, will cause problems
by recurring and eventually reseeding the marrow. For others
it is a marker of more widespread disease already present. In
those, central nervous system control with irradiation alone
would merely lead to the initial relapse occurring in a non-
CNS site.
Initially the use of craniospinal irradiation, although
effective, was associated with excessive and unacceptable
marrow ablation from the spinal component and the 'gold
standard' therapy pioneered by the St Jude group was 24Gy
in 14-15 fractions over 17-18 days with intrathecal
methotrexate, initially in a dose of 12 mg m-2 x 5 given every
3-4 days. Radiation doses were scaled down for young
children (20 Gy for 1-year-olds and 15 Gy for those <1
year). Higher fraction dosage, less fractions per week and
longer duration of total therapy have not been shown to be
advantageous. Modifications which do appear to have been
worthwhile are the adjustment of methotrexate dosage by age
which appears to correlate better with CSF volume than
surface area and toxicity has been reduced by using weekly
rather than twice weekly lumbar punctures without apparent
loss of efficacy. The Children's Cancer Study Group (CCSG)
have demonstrated that for those with an initial peripheral
white count <50 x 1091-', 18 Gy is as effective as 24Gy
(Nesbit et al., 1981). For those with higher initial white cell
counts there was a trend for better CNS control with 24 Gy
(of borderline statistical significance).
It is the toxicity of this therapy which has caused partic-
ular anxiety and led to approaches which avoid combined
modality therapy, particularly CNS irradiation, whenever
possible. Acute neurotoxicity during cranial irradiation is
rare apart from somnolence syndrome (symptoms maybe
lessened by concomitant steroids), but immediate post-
radiotherapy severe immunosuppression, partial or complete
growth hormone deficiency, premature onset of puberty and
most significantly intellectual impairment are worrying
sequelae from CNS therapy. Intellectual impairment is worst
in children under 3 years at diagnosis and although they may
function intellectually within the normal range they perform
less well than siblings or peer group controls. Short-term
memory appears to be specifically affected and this can be a
major handicap in the achievement of basic numeracy and
literacy (Eiser & Lansdown, 1977; Janoun, 1983). To date the
reduction from 24 to 18 Gy does not appear to decrease this
risk. In the long term there may be a correlation between
neuropsychological changes and abnormalities reported on
CT and MRI scanning (Brouwers et al., 1985). Although
periventricular hypodensities may disappear with time it may
be years before calcification develops, and therefore very
long-term assessment is required before reliable conclusions
can be drawn on toxicity.
The search is thus on for a group of children in whom
cranial irradiation can be avoided without jeopardy to their
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survival and conversely identification of those where there is
no alternative. Green et al. (1980) retrospectively reviewed a
number of studies comparing those given standard therapy
with radiation and intrathecal methotrexate and those who
either received a prolonged course of triple intrathecal
chemotherapy only and those receiving intermediate dose
systemic methotrexate plus intrathecal methotrexate. The
lowest CNS relapse rates (reaching significance) were
recorded for those given irradiation in both standard
(P<0.05) and high risk categories (P<0.001), but the
lowest haematological relapse rate for standard risk patients
was achieved with systemic intermediate dose methotrexate.
In the high risk patients the best relapse-free and total sur-
vival was obtained with irradiation. Where there was a high
CNS relapse rate total survival was poorest, but where it was
lowest it did not necessarily predict for overall good survival.
The most important point appeared to be to achieve the best
systemic leukaemia cell kill. This was a review and not a
randomised concurrent trial and the systemic methotrexate
dosages were low by current standards. High dose systemic
therapy in dosages of 6-8 gm-2 give cytocidal concentra-
tions (10- m) for 24-36 hours (Bleyer, 1989). Appropriately
phased folinic acid rescues normal cells outside the CNS and
possibly blasts there, but not those within the CNS provided
the rescue is given when the CSF methotrexate concentration
falls below the concentration cytotoxic to the leukaemic cells.
Such, therapy may not require the addition of intrathecal
therapy. In a series of escalating dose studies the NCI
and CCSG (Poplack et al., 1984) have showed that for
intermediate and poor risk patients such methotrexate
therapy is as effective as 24 Gy cranial radiotherapy with
standard intrathecal methotrexate. They have also investi-
gated the relative toxicities of the different forms of CNS
treatment. Those irradiated showed a steady decline in verbal
IQ and in full scale IQ whilst those receiving methotrexate
demonstrated a slight increase in both parameters with a
marginal fall in results of arithmetic tests. Patients who had
been irradiated showed a decline in reading, spelling and
arithmetic tests (Brouwers, 1987). There must be some reser-
vations about these observations. Follow-up is relatively
short at 4-5 years and repeat testing can give spurious
results. Most previous studies have suggested that post-
irradiation verbal IQ is relatively spared and that the normal
deterioration is in non-verbal performance.
Some questions remain and we cannot be absolutely
confident that there will be no long-term sequelae from these
high doses of systemic methotrexate, but the NCI/CCSG's
studies included patients receiving dosages as high as
33 g m-2. Repeatedly studies have demonstrated that the
more modalities used for CNS minimal disease treatment the
higher the risk of toxicity and that systemic methotrexate
alone appears to be the least toxic, but still effective of the
modalities. Intrathecal therapy with methotrexate alone may
be marginally more toxic, but certainly less effective. There
are strong suggestions from the POG group that triple intra-
thecal therapy with methotrexate, cytosine and hydro-
cortisone may be effective enough at preventing CNS relapse
in at least low-risk patients. However, we have not good
long-term evidence with regard to toxicity. The worst risk is
undoubtedly the combination of radiotherapy, intrathecal
methotrexate and systemic methotrexate, especially when
given in that sequence. To date no group of children has
been demonstrated to have no risk of overt CNS relapse, but
there may be some with very low risk. In the Medical
Research Council UKALL VIII Study where the majority of
patients received 18 Gy plus six intrathecal methotrexate
injections, but only those with initial white counts
> 100 x 109 1' received 24 Gy, the isolated CNS relapse rate
was 1.4% for girls aged 3-6 years with a white count < 10
for all other patients with a white count up to 50 x 109 [' it
was approximately 7% and above that white count 11- 12%
with a slight sex difference (Eden et al., 1989).
In the future, we may be able to define those girls who
truly do not need any CNS treatment, meanwhile it would
seem reasonable to try to avoid irradiation in those with
standard risk (white count up to 50 x 109 I-') but use
systemic methotrexate which may also afford some initial
benefit in terms of overall disease-free survival. For the high
risk patients matters are less clear, but a randomisation
between irradiation and systemic methotrexate would appear
justified. These form the basis of the next Medical Research
Council ALL Trial with no change otherwise in the well
established systemic treatment. The emphasis throughout
must be upon total body leukaemia cell kill without overdue
preoccupation with specific focal sites. High-dose systemic
methotrexate in dosages between 6 and 10 gm2 seem to
offer the chance of this without evidence to date of excessive
toxicity. It is essential that such modern studies must incor-
porate assessment of toxicity.
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